Brief: Oncoarendi Therapeutics Signs Deal For Exclusive Licence Of Protein Inhibitors With University Of Michigan

Molecure SA

11/03/2022 17:16

March 11 (Reuters) - Oncoarendi Therapeutics SA  OAT.WA :
    * SAYS SIGNS OPTIONAL DEAL FOR EXCLUSIVE LICENCE FOR PROTEIN
INHIBITORS DEVELOPED BY UNIVERSITY OF MICHIGAN AND MICHIGAN
STATE UNIVERSITY
    * SAYS SIGNED SAID DEAL WITH UNIVERSITY OF MICHIGAN
    * SAYS INHIBITORS HAVE CONFIRMED ANTIFIBROTIC EFFECT ON
ANIMAL
MODELS
    * SAYS OPTIONAL DEAL STIPULATES 6-MONTH EXCLUSIVITY PERIOD
    * SAYS LEADING MOLECULE UNDER NEW CLASS OF COMPOUNDS MAY
SIGNIFICANTLY BOOST COMPANY'S PROJECT PIPELINE

Source text for Eikon:  ID:nEM3bcnLta 
Further company coverage:  OAT.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))